China Jo-Jo Drugstores, Inc. (CJJD)
USD 1.52
(-5.59%)
USD 1.52
(-5.59%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 34.64 Million USD | -22.75% |
| 2023 | 44.84 Million USD | 14.8% |
| 2022 | 39.06 Million USD | 3.2% |
| 2021 | 37.85 Million USD | 18.65% |
| 2020 | 31.9 Million USD | 22.77% |
| 2019 | 25.98 Million USD | -28.93% |
| 2018 | 36.56 Million USD | 77.42% |
| 2017 | 20.6 Million USD | 17.52% |
| 2016 | 17.53 Million USD | 63.44% |
| 2015 | 10.72 Million USD | -57.01% |
| 2014 | 24.95 Million USD | -8.3% |
| 2013 | 27.21 Million USD | 59.35% |
| 2012 | 17.08 Million USD | 78.62% |
| 2011 | 9.56 Million USD | 130.96% |
| 2010 | 4.14 Million USD | 14302.69% |
| 2009 | 28.74 Thousand USD | 669.28% |
| 2008 | 3737.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 9.37 Million USD | 0.0% |
| 2024 Q2 | 8.51 Million USD | 0.0% |
| 2024 FY | 34.64 Million USD | -22.75% |
| 2024 Q3 | 9.37 Million USD | 10.06% |
| 2024 Q1 | 8.51 Million USD | -55.96% |
| 2023 Q2 | 8.58 Million USD | 0.0% |
| 2023 Q1 | 8.58 Million USD | -62.97% |
| 2023 Q3 | 19.34 Million USD | 125.39% |
| 2023 Q4 | 19.34 Million USD | 0.0% |
| 2023 FY | 44.84 Million USD | 14.8% |
| 2022 Q2 | 15.89 Million USD | 103.52% |
| 2022 Q3 | 11.57 Million USD | -27.19% |
| 2022 Q4 | 23.17 Million USD | 100.28% |
| 2022 Q1 | 7.8 Million USD | 20.72% |
| 2022 FY | 39.06 Million USD | 3.2% |
| 2021 FY | 37.85 Million USD | 18.65% |
| 2021 Q1 | 8.39 Million USD | 4.36% |
| 2021 Q3 | 14.45 Million USD | 69.32% |
| 2021 Q4 | 6.46 Million USD | -55.25% |
| 2021 Q2 | 8.53 Million USD | 1.72% |
| 2020 FY | 31.9 Million USD | 22.77% |
| 2020 Q4 | 8.04 Million USD | 19.48% |
| 2020 Q3 | 6.73 Million USD | -19.01% |
| 2020 Q2 | 8.3 Million USD | -5.79% |
| 2020 Q1 | 8.82 Million USD | 184.32% |
| 2019 Q4 | 3.1 Million USD | -66.5% |
| 2019 Q2 | 7.43 Million USD | 20.34% |
| 2019 FY | 25.98 Million USD | -28.93% |
| 2019 Q3 | 9.26 Million USD | 24.5% |
| 2019 Q1 | 6.18 Million USD | -61.26% |
| 2018 Q2 | 7.2 Million USD | 27.72% |
| 2018 FY | 36.56 Million USD | 77.42% |
| 2018 Q1 | 5.64 Million USD | -14.24% |
| 2018 Q3 | 7.75 Million USD | 7.67% |
| 2018 Q4 | 15.95 Million USD | 105.65% |
| 2017 Q3 | 5.02 Million USD | 13.98% |
| 2017 FY | 20.6 Million USD | 17.52% |
| 2017 Q4 | 6.57 Million USD | 31.0% |
| 2017 Q2 | 4.4 Million USD | -4.24% |
| 2017 Q1 | 4.6 Million USD | 12.06% |
| 2016 Q4 | 4.1 Million USD | -20.35% |
| 2016 Q2 | 4.25 Million USD | 6.02% |
| 2016 Q3 | 5.15 Million USD | 21.05% |
| 2016 FY | 17.53 Million USD | 63.44% |
| 2016 Q1 | 4.01 Million USD | 67.79% |
| 2015 Q4 | 2.39 Million USD | -14.7% |
| 2015 Q2 | 2.67 Million USD | -5.96% |
| 2015 Q1 | 2.84 Million USD | -64.93% |
| 2015 FY | 10.72 Million USD | -57.01% |
| 2015 Q3 | 2.8 Million USD | 4.71% |
| 2014 Q2 | 3.47 Million USD | -19.68% |
| 2014 Q3 | 9.03 Million USD | 160.4% |
| 2014 Q4 | 8.12 Million USD | -10.1% |
| 2014 Q1 | 4.32 Million USD | -65.76% |
| 2014 FY | 24.95 Million USD | -8.3% |
| 2013 Q2 | 3.41 Million USD | -27.46% |
| 2013 Q4 | 12.62 Million USD | 94.78% |
| 2013 Q3 | 6.47 Million USD | 89.84% |
| 2013 Q1 | 4.7 Million USD | -20.54% |
| 2013 FY | 27.21 Million USD | 59.35% |
| 2012 Q4 | 5.92 Million USD | 26.67% |
| 2012 FY | 17.08 Million USD | 78.62% |
| 2012 Q3 | 4.67 Million USD | 15.93% |
| 2012 Q2 | 4.03 Million USD | 64.37% |
| 2012 Q1 | 2.45 Million USD | -29.19% |
| 2011 Q1 | 1.59 Million USD | 104.28% |
| 2011 Q4 | 3.46 Million USD | 35.08% |
| 2011 Q3 | 2.56 Million USD | 32.41% |
| 2011 FY | 9.56 Million USD | 130.96% |
| 2011 Q2 | 1.93 Million USD | 21.27% |
| 2010 FY | 4.14 Million USD | 14302.69% |
| 2010 Q4 | 781.81 Thousand USD | -42.27% |
| 2010 Q2 | 1.16 Million USD | 98784.45% |
| 2010 Q3 | 1.35 Million USD | 16.59% |
| 2010 Q1 | -1177.00 USD | -127.62% |
| 2009 Q4 | 4261.00 USD | -22.37% |
| 2009 Q1 | 4001.00 USD | -76.2% |
| 2009 Q3 | 5489.00 USD | 380.23% |
| 2009 FY | 28.74 Thousand USD | 669.28% |
| 2009 Q2 | 1143.00 USD | -71.43% |
| 2008 Q2 | 859.00 USD | 0.0% |
| 2008 Q4 | 16.8 Thousand USD | 137.45% |
| 2008 FY | 3737.00 USD | 0.0% |
| 2008 Q3 | 7079.00 USD | 724.1% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | 13.47 Million USD | -157.044% |
| BIMI International Medical Inc. | 17.28 Million USD | -100.384% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | 89.97 Million USD | 61.496% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | 90.12 Million USD | 61.56% |
| Leafly Holdings, Inc. | 44.5 Million USD | 22.154% |
| Leafly Holdings, Inc. | 44.5 Million USD | 22.154% |
| LifeMD, Inc. | 148.13 Million USD | 76.614% |
| LifeMD, Inc. | 148.13 Million USD | 76.614% |
| TRxADE HEALTH, Inc. | 9.86 Million USD | -251.291% |
| PetMed Express, Inc. | 86.81 Million USD | 60.093% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.915% |